Elena C. D. J.
- Country
- Spain
- Department
- N/A
Research Overview
- Phase IV, Open-label, Multi-center Rollover Study of Crizanlizumab in Patients with Sickle Cell Disease Post-Novartis-Sponsored Study Completion
- Phase 3 Randomized Double-Blind Placebo-Controlled Trial of Etavopivat in Adolescents and Adults with Sickle Cell Disease
- Evaluation of Safety, Efficacy, and Pharmacokinetics of CSL889 (Human Hemopexin) in Sickle Cell Disease Patients Experiencing Vaso-Occlusive Crisis
Data & Insights
Has run more than one trial at 29 of 56 partner sites.
Specializations
Sickle Cell Disease Management
This investigator specializes in sickle cell disease (SCD) therapeutics, with particular emphasis on innovative treatment approaches and disease management strategies.
- Novel therapeutic agents evaluation
- Long-term treatment optimization
- Disease progression monitoring
The research focuses on evaluating various therapeutic compounds including crizanlizumab and etavopivat for SCD treatment.
Vaso-Occlusive Crisis Research
Specialized investigation into vaso-occlusive episodes (VOE) management, including both preventive approaches and acute treatment strategies.
- Crisis intervention protocols
- Prevention strategies
- Treatment response assessment
Primary focus includes evaluation of hemopexin-based therapies and novel compounds for VOE management.
Therapeutic Innovation
Expertise in assessing emerging therapeutic approaches for SCD, including evaluation of novel biological agents and treatment protocols.
- Pharmacokinetic studies
- Safety profile assessment
- Treatment efficacy evaluation
Investigation includes studies of crovalimab and other innovative compounds for SCD treatment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.